Drug Trial Radar · NCT06495918
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
Last checked: Nov 20, 2026Latest source record: Jun 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
825
Planned (sponsor's estimate)
Start
Nov 27, 2024
Primary completion
Jan 8, 2027
Study completion Jan 8, 2027
Sponsor
- Lead sponsor
- Ocular Therapeutix, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Fortrea; Duke University
- First posted
- Jul 11, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects with Neovascular Age- Related Macular Degeneration
Conditions
- Neovascular Age-related Macular Degeneration
Interventions
OTX-TKIDrug
Intravitreal Injection of OTX-TKI
AfliberceptDrug
Intravitreal Injection of 2mg of aflibercept
AfliberceptDrug
Intravitreal Injection of 8mg of aflibercept
Primary outcomes
What the sponsor says the trial is designed to measure.
- Best Corrected Visual Acuity (BCVA)Time frame: Week 48
Locations
97 sites in 4 countries. Site status is shown where the registry gives one.
Associated Retina Consultant
Gilbert, Arizona
Associated Retina Consultants, Ltd.
Phoenix, Arizona
Retinal Research Institute, LLC
Phoenix, Arizona
Retina Macula Institute of Arizona
Scottsdale, Arizona
California Retina Consultants
Bakersfield, California
The Retina Partners
Encino, California
Retina Consultants of Orange County
Fullerton, California
Atlantis Eyecare
Huntington Beach, California
Salehi Retina Institute, Inc., dba Retina Associates of Southern California
Huntington Beach, California
Kaiser Permanente Division of Research
Oakland, California
California Retina Consultants
Oxnard, California
Stanford Health Care - Byers Eye Institute
Palo Alto, California
Stanford University School of Medicine, Byers Eye Institute
Palo Alto, California
California Eye Specialists Medical Group, INC
Pasadena, California
Retinal Consultants Medical Group
Sacramento, California
Orange County Retina Medical Group
Santa Ana, California
California Retina Consultants
Santa Barbara, California
Macula Retina Vitreous Research Institute
Torrance, California
Bay Area Retina Associates
Walnut Creek, California
Retina Consultants of Southern Colorado
Colorado Springs, Colorado
RSC Research, LLC
Denver, Colorado
Colorado Retina Associates
Lakewood, Colorado
Retina Consultants, P.C
Manchester, Connecticut
Retina Group of New England
Waterford, Connecticut
Advanced Research LLC.
Deerfield Beach, Florida
Rand Eye Institute
Deerfield Beach, Florida
Retina Group of Florida
Fort Lauderdale, Florida
Florida Retina Consultants
Lakeland, Florida
South Florida Retina Institute
Miami, Florida
Florida Retina Institude
Orlando, Florida
Retina Specialty Institute
Pensacola, Florida
MedEye Associates
South Miami, Florida
Retina Vitreous Associates of Florida- Saint Petersburg
St. Petersburg, Florida
Retina Vitreous Associates of Florida
Tampa, Florida
Southeast Retina Center
Augusta, Georgia
University Retina and Macula Associates, PC
Oak Forest, Illinois
Illinois Retina Associates
Oak Park, Illinois
Springfield Clinic Opthalmology Department
Springfield, Illinois
Associate Vitreoretinal and Uveitis Consultants
Carmel, Indiana
Retina Partners Midwest, P.C.
Carmel, Indiana
Showing 40 of 97 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.